CoChat

Pioglitazone and bladder cancer risk: a multipopulation pooled, cumulative exposure analysis

Open access
on behalf of the Scottish Diabetes Research Network Epidemiology Group and the Diabetes and Cancer Research Consortium, Levin, Daniel, Bell, Samira, Sund, Reijo, Hartikainen, Sirpa A., Tuomilehto, Jaakko, Pukkala, Eero, Keskimäki, Ilmo, Badrick, Ellena, Renehan, Andrew G., Buchan, Iain E., Bowker, Samantha L., Minhas-Sandhu, Jasjeet K., Zafari, Zafar, Marra, Carlo, Johnson, Jeffrey A., Stricker, Bruno H., Uitterlinden, Andrè G., Hofman, Albert, Ruiter, Rikje, de Keyser, Catherine E., MacDonald, Thomas M., Wild, Sarah H., McKeigue, Paul M., Colhoun, Helen M. · 2015 · Diabetologia

The DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.

Abstract

AIMS/HYPOTHESIS: The evidence on the association between pioglitazone use and bladder cancer is contradictory, with many studies subject to allocation bias. The aim of our study was to examine the effect of exposure to pioglitazone on bladder cancer risk internationally across several cohorts. The potential for allocation bias was minimised by focusing on the cumulative effect of pioglitazone as the primary endpoint using a time-dependent approach. METHODS: Prescription, cancer and mortality data from people with type 2 diabetes were obtained from six populations across the world (British Columbia, Finland, Manchester, Rotterdam, Scotland and the UK Clinical Practice Research Datalink). A discrete time failure analysis using Poisson regression was applied separately to data from each centre to model the effect of cumulative drug exposure on bladder cancer incidence, with time-dependent adjustment for ever use of pioglitazone. These were then pooled using fixed and random effects meta-regression. RESULTS: Data were collated on 1.01 million persons over 5.9 million person-years. There were 3,248 cases of incident bladder cancer, with 117 exposed cases and a median follow-up duration of 4.0 to 7.4 years. Overall, there was no evidence for any association between cumulative exposure to pioglitazone and bladder cancer in men (rate ratio [RR] per 100 days of cumulative exposure, 1.01; 95% CI 0.97, 1.06) or women (RR 1.04; 95% CI 0.97, 1.11) after adjustment for age, calendar year, diabetes duration, smoking and any ever use of pioglitazone. No association was observed between rosiglitazone and bladder cancer in men (RR 1.01; 95% CI 0.98, 1.03) or women (RR 1.00; 95% CI 0.94, 1.07). CONCLUSIONS/INTERPRETATION: The cumulative use of pioglitazone or rosiglitazone was not associated with the incidence of bladder cancer in this large, pooled multipopulation analysis.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1007/s00125-014-3456-9

Cites

32 of 32 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 32 references

Cited by

See all 169

Metadata

Authors
on behalf of the Scottish Diabetes Research Network Epidemiology Group and the Diabetes and Cancer Research Consortium, Levin, D., Bell, S., Sund, R., Hartikainen, S. A., Tuomilehto, J., Pukkala, E., Keskimäki, I., Badrick, E., Renehan, A. G., Buchan, I. E., Bowker, S. L., Minhas-Sandhu, J. K., Zafari, Z., Marra, C., Johnson, J. A., Stricker, B. H., Uitterlinden, A. G., Hofman, A., Ruiter, R., de Keyser, C. E., MacDonald, T. M., Wild, S. H., McKeigue, P. M., & Colhoun, H. M.
Affiliations
  • University of Dundee (GB)
  • Ninewells Hospital (GB)
  • University of Helsinki (FI)
  • University of Eastern Finland (FI)
  • Universität für Weiterbildung Krems (AT)
  • Finnish Cancer Registry (FI)
  • Finnish Institute for Health and Welfare (FI)
  • University of Manchester (GB)
  • University of Alberta (CA)
  • University of British Columbia (CA)
  • Erasmus MC (NL)
  • Groene Hart Ziekenhuis (NL)
  • University of Edinburgh (GB)
Corresponding author
Bell, Samira
Venue
Diabetologia
Published
2014-12-07
Volume
58
Issue
3
Pages
493-504
ISSN
  • 0012-186X (ISSN-L)
  • 1432-0428
OpenAlex
W2069723602
Cited by
158
References
32
Citations by year
2026: 3 · 2025: 5 · 2024: 9 · 2023: 4 · 2022: 7 · 2021: 5 · 2020: 6 · 2019: 9 · 2018: 14 · 2017: 25 · 2016: 37 · 2015: 33 · 2014: 1
FWCI
13.11
Type
journal article
Language
en
Open access
Licence
www.springer.com/tdm (tdm)
Locations
  • Diabetologia (publishedVersion)
  • PubMed (publishedVersion)
  • Research Explorer (The University of Manchester) (publishedVersion)
  • EUR Research Repository (Erasmus University Rotterdam) (publishedVersion)
  • EUR Research Repository (Erasmus University Rotterdam) (submittedVersion)
  • Discovery Research Portal (University of Dundee) (submittedVersion)
  • STM:n Hallinnonalan avoin julkaisuarkisto (Julkari) (submittedVersion)
  • WOS
Funders
  • University of Dundee
  • European Foundation for the Study of Diabetes
  • Medical Research Council (MR/K006665/1, MR/M501633/1, MC_PC_13042, MR/K007017/1)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Metabolism, Diabetes, and Cancer
  • Health Sciences › Medicine › Surgery › Bladder and Urothelial Cancer Treatments
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
Keywords
pioglitazone, rosiglitazone, bladder cancer, type 2 diabetes, thiazolidinediones, drug-induced cancer risk, cumulative drug exposure, allocation bias, cancer incidence, pooled analysis
MeSH terms
Rosiglitazone, Pioglitazone, Aged, Urinary Bladder Neoplasms, British Columbia, Diabetes Mellitus, Type 2, Female, Finland, Humans, Hypoglycemic Agents, Male, Middle Aged, Scotland, Incidence, Thiazolidinediones

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Pioglitazone and bladder cancer risk: a multipopulation pooled, cumulative exposure analysis. https://app.cochat.ai/papers/10.1007/s00125-014-3456-9
The paper
on behalf of the Scottish Diabetes Research Network Epidemiology Group and the Diabetes and Cancer Research Consortium, Levin, D., Bell, S., Sund, R., Hartikainen, S. A., Tuomilehto, J., Pukkala, E., Keskimäki, I., Badrick, E., Renehan, A. G., Buchan, I. E., Bowker, S. L., Minhas-Sandhu, J. K., Zafari, Z., Marra, C., Johnson, J. A., Stricker, B. H., Uitterlinden, A. G., Hofman, A., . . . Colhoun, H. M. (2015). Pioglitazone and bladder cancer risk: a multipopulation pooled, cumulative exposure analysis. Diabetologia. https://doi.org/10.1007/s00125-014-3456-9

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.